Abstract
Ten consecutive patients with motor neuron disease (MND) who had bulbar symptoms received one or two intravenous doses followed by increasing oral doses of a TRH analogue (RX77368). Similar improvements in speech, swallowing and in tongue and jaw movements were seen after iv and oral administration in nine, five and eight patients respectively. The initial time course of improvement correlated with increasing plasma levels of the drug, but most clinical effects persisted when the levels decreased and became undetectable after 24 hours. The oral solution was tasteless and had no, or minimal, side effects.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Guiloff R. J., Eckland D. J., Demaine C., Hoare R. C., MacRae K. D., Lightman S. L. Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease. J Neurol Neurosurg Psychiatry. 1987 Oct;50(10):1359–1370. doi: 10.1136/jnnp.50.10.1359. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Guiloff R. J. Use of TRH analogues in motorneurone disease. Ann N Y Acad Sci. 1989;553:399–421. doi: 10.1111/j.1749-6632.1989.tb46662.x. [DOI] [PubMed] [Google Scholar]
- Mendez M. F., Geehan G. R., Jr Cortical auditory disorders: clinical and psychoacoustic features. J Neurol Neurosurg Psychiatry. 1988 Jan;51(1):1–9. doi: 10.1136/jnnp.51.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ogawa N., Mizuno S., Nukina I., Tsukamoto S., Mori A. Chronic thyrotropin releasing hormone (TRH) administration on TRH receptors and muscarinic cholinergic receptors in CNS. Brain Res. 1983 Mar 21;263(2):348–350. doi: 10.1016/0006-8993(83)90328-1. [DOI] [PubMed] [Google Scholar]
- Simasko S. M., Horita A. Treatment of rats with the TRH analog MK-771. Down-regulation of TRH receptors and behavioral tolerance. Neuropharmacology. 1985 Feb;24(2):157–165. doi: 10.1016/0028-3908(85)90175-3. [DOI] [PubMed] [Google Scholar]